Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pharmacielo stock price, quote, forecast and news

PCLO.V
CA71716K1012
A2PCAX

Price

0.12
Today +/-
+0
Today %
+0 %
P

Pharmacielo stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Pharmacielo stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pharmacielo stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pharmacielo stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pharmacielo's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pharmacielo Stock Price History

DatePharmacielo Price
9/19/20240.12 undefined
9/18/20240.12 undefined
9/17/20240.12 undefined
9/16/20240.12 undefined
9/13/20240.11 undefined
9/12/20240.09 undefined
9/11/20240.10 undefined
9/10/20240.10 undefined
9/9/20240.10 undefined
9/6/20240.11 undefined
9/5/20240.11 undefined
9/4/20240.11 undefined
9/3/20240.10 undefined
8/30/20240.11 undefined
8/29/20240.11 undefined
8/28/20240.13 undefined
8/27/20240.13 undefined
8/26/20240.14 undefined
8/23/20240.14 undefined
8/22/20240.12 undefined

Pharmacielo Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Pharmacielo, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharmacielo from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharmacielo’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pharmacielo. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pharmacielo’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pharmacielo’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharmacielo’s growth potential.

Pharmacielo Revenue, EBIT and net profit per share

DatePharmacielo RevenuePharmacielo EBITPharmacielo Net Income
2025e296.23 M undefined42.87 M undefined39.49 M undefined
2024e118.49 M undefined29.12 M undefined28.36 M undefined
20231.54 M undefined-10.56 M undefined-16.3 M undefined
20225.31 M undefined-10.53 M undefined-14.52 M undefined
20211.95 M undefined-23.96 M undefined-26.63 M undefined
20202.65 M undefined-41.8 M undefined-43.76 M undefined
2019786,900 undefined-32.56 M undefined-34.67 M undefined
20180 undefined-144,400 undefined-144,400 undefined

Pharmacielo Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e
002151118296
----50.00400.00-80.0011,700.00150.85
---250.00-300.0020.00-100.00--
00-5,000-3,0001,000-1,00000
0-32-41-23-10-102942
---2,050.00-2,300.00-200.00-1,000.0024.5814.19
0-34-43-26-14-162839
--26.47-39.53-46.1514.29-275.0039.29
0.1296.05112.54145.64150.98160.0800
--------
Details

Keystats

Revenue and Growth

The Pharmacielo Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pharmacielo is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20182019202020212022
         
0.2113.789.615.630.33
0709.49352.67277.05611.49
01.110.570.290.06
03.641.252.282.13
0426.62732.08721.3889.2
0.2119.6712.529.24.02
028.7230.8226.1220.62
00565.4639.64472.99
00028859
0639.8120.1100
01.16000
00000
030.5231.5127.0521.16
0.2150.244.0236.2425.17
         
0.29116.83138.64158.29162.27
00000
-0.1-71.27-109.81-132.76-147.19
0-0.09-2.58-6.21-8.69
00000
0.1945.4726.2519.336.39
0.022.911.717.736.11
00011226
0258.17105.26111.7825.93
00000
0147.6242.85227.28816.79
0.023.3112.068.186.98
01.424.238.211.77
00000
001.490.360
01.425.728.5611.77
0.024.7317.7816.7418.75
0.2150.244.0236.0725.14
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Pharmacielo provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pharmacielo's financial health and stability.

Assets

Pharmacielo's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pharmacielo must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pharmacielo after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pharmacielo's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20182019202020212022
0-34-43-26-14
01,0001,0001,0001,000
00000
0-43-7-1
01216125
00000
00000
0-25-22-20-9
0-11-5-10
0-11-5-10
00000
00000
00245
0522140
0423185
---1.00-1.00-
00000
0-32-4-3-5
-0.08-36.62-28-21.21-10.23
00000

Pharmacielo stock margins

The Pharmacielo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharmacielo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharmacielo.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pharmacielo's sales revenue. A higher gross margin percentage indicates that the Pharmacielo retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pharmacielo's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pharmacielo's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharmacielo's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharmacielo. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharmacielo's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pharmacielo Margin History

Pharmacielo Gross marginPharmacielo Profit marginPharmacielo EBIT marginPharmacielo Profit margin
2025e-122.1 %14.47 %13.33 %
2024e-122.1 %24.57 %23.93 %
2023-122.1 %-684.69 %-1,057.09 %
202229.93 %-198.3 %-273.45 %
2021-158 %-1,231.8 %-1,369.14 %
2020-189.76 %-1,574.89 %-1,648.72 %
2019-14.51 %-4,137.83 %-4,405.56 %
2018-122.1 %0 %0 %

Pharmacielo Stock Sales Revenue, EBIT, Earnings per Share

The Pharmacielo earnings per share therefore indicates how much revenue Pharmacielo has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Pharmacielo earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharmacielo's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharmacielo’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharmacielo's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharmacielo Revenue, EBIT and net profit per share

DatePharmacielo Sales per SharePharmacielo EBIT per sharePharmacielo Earnings per Share
2025e1.75 undefined0 undefined0.23 undefined
2024e0.7 undefined0 undefined0.17 undefined
20230.01 undefined-0.07 undefined-0.1 undefined
20220.04 undefined-0.07 undefined-0.1 undefined
20210.01 undefined-0.16 undefined-0.18 undefined
20200.02 undefined-0.37 undefined-0.39 undefined
20190.01 undefined-0.34 undefined-0.36 undefined
20180 undefined-1.18 undefined-1.18 undefined

Pharmacielo business model

Pharmacielo Ltd is a company specializing in the production of medical cannabis products. The company is based in Canada, but its production facilities are located in Colombia, one of the most important cultivation areas for cannabis worldwide. The company was founded in 2014 by individuals with experience in commercial cultivation of crops. Its goal is to establish a safe and efficient production of medical cannabis in Colombia to ensure high-quality and affordable supply for patients worldwide. Pharmacielo Ltd's business model is based on the production and delivery of medical cannabis products to customers worldwide. The company produces cannabis flowers, extracts, and oils that are used to treat various medical conditions such as cancer, chronic pain, and neurological disorders. Pharmacielo Ltd works closely with the Colombian government to regulate and standardize the cultivation of medical cannabis to ensure high quality and purity of its products. The company has already received various certifications and approvals confirming the quality and safety of its products. Pharmacielo Ltd is divided into different divisions specializing in production and logistics. The "Production" division is responsible for the cultivation and harvesting of cannabis. Pharmacielo Ltd collaborates with various partners to ensure a large production capacity. The "Extraction" division is responsible for the production of medical cannabis extracts and oils. The dried cannabis flowers are dissolved in a liquid and then extracted to isolate the desired components. The "Logistics" division is responsible for the delivery of products to customers worldwide. The company works with various shipping service providers to ensure fast and reliable delivery of its products. Pharmacielo Ltd offers a wide range of products made from medical cannabis, including cannabis flowers in different varieties and sizes that can be selected based on individual needs. Additionally, products such as oils, extracts, and capsules are offered, which have a higher concentration of cannabinoids and are therefore particularly suitable for the treatment of serious illnesses such as cancer or epilepsy. Overall, Pharmacielo Ltd has become a leading company in the production and delivery of medical cannabis in recent years. The company works closely with the government and other companies to ensure a safe and reliable supply for patients worldwide. With its wide range of products and innovative production technology, Pharmacielo Ltd is well positioned to continue growing and meeting the needs of customers in the future. Pharmacielo is one of the most popular companies on Eulerpool.com.

Pharmacielo SWOT Analysis

Strengths

Pharmacielo Ltd is a leading player in the pharmaceutical industry, specializing in the production and distribution of medicinal cannabis products. Its competitive advantage lies in several key areas.

  • Strong global presence: Pharmacielo has established a strong presence in multiple countries, allowing it to tap into different markets and diversify its revenue streams.
  • Expertise in cannabis production: With a team of experienced professionals, Pharmacielo has developed advanced cultivation and extraction techniques to ensure high-quality cannabis products.
  • Strategic partnerships: The company has formed strategic partnerships with key players in the pharmaceutical and healthcare sectors, allowing for collaboration and access to distribution networks.
  • Strong brand image: Pharmacielo has built a reputable brand known for its commitment to quality, safety, and innovation in the cannabis industry.

Weaknesses

Despite its strengths, Pharmacielo also faces certain weaknesses that could pose challenges to its success.

  • Regulatory hurdles: The cannabis industry operates within a complex and evolving regulatory framework, leading to potential challenges in obtaining necessary licenses and permits.
  • Reliance on external suppliers: Pharmacielo may face supply chain disruptions or quality control issues if it relies heavily on external suppliers for raw materials or components.
  • Limited product diversification: While the company is a leader in cannabis production, its operations primarily focus on medicinal cannabis products, limiting its ability to tap into other segments of the pharmaceutical market.

Opportunities

Pharmacielo has identified several opportunities that could drive its growth and expansion in the future.

  • Increasing legalization of cannabis: As more countries legalize the use of cannabis for medical and recreational purposes, there is a growing market potential for Pharmacielo's products.
  • Rising consumer awareness: The increased awareness and acceptance of the potential health benefits of cannabis present an opportunity for Pharmacielo to educate and capture a larger customer base.
  • Expansion into new markets: Pharmacielo can explore new geographic markets and expand its operations to capitalize on the global demand for cannabis products.

Threats

Pharmacielo must also be aware of potential threats that could affect its business operations and market position.

  • Intense competition: The cannabis industry is highly competitive, with the presence of both established players and new entrants. Pharmacielo could face challenges in maintaining market share amidst intense competition.
  • Regulatory risks: Changes in regulations or unfavorable government policies can significantly impact Pharmacielo's operations and market access.
  • Product quality and safety concerns: Any incidents related to product quality, safety, or adverse effects could lead to reputational damage and legal liabilities.

Pharmacielo Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pharmacielo historical P/E ratio, EBIT, and P/S ratio.

Pharmacielo shares outstanding

The number of shares was Pharmacielo in 2023 — This indicates how many shares 160.081 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Pharmacielo earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharmacielo's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharmacielo’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharmacielo's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharmacielo Stock splits

In Pharmacielo's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Pharmacielo.

Pharmacielo latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2021-0.03 -0.06  (-98.02 %)2021 Q3
6/30/2021-0.03 -0.04  (-32.01 %)2021 Q2
3/31/20210.05 -0.05  (-199.01 %)2021 Q1
12/31/20200.02 -0.16  (-892.08 %)2020 Q4
9/30/20200.01 -0.05  (-595.05 %)2020 Q3
6/30/2020-0.04 -0.07  (-73.27 %)2020 Q2
3/31/2020-0.1 -0.07  (30.83 %)2020 Q1
12/31/2019-0.04 -0.13  (-205.95 %)2019 Q4
9/30/2019-0.09 -0.04  (57.41 %)2019 Q3
6/30/2019-0.05 -0.11  (-103.11 %)2019 Q2
1
2

Pharmacielo list of shareholders

%
Name
Stocks
Change
Date
7.43925 % Lustig (Marc)12,627,7628,678,6261/16/2024
4.60112 % Wasatch Global Investors Inc7,810,171012/31/2023
0.65570 % Petron (William Boris)1,113,013-2,584,4391/16/2024
0.32145 % Atacan, Ian D545,64601/17/2024
0.29154 % Penserra Capital Management LLC494,8705007/31/2022
0.19941 % AdvisorShares Investments, LLC338,496-4,55612/31/2023
0.04124 % Bache (Douglas H)70,00001/16/2024
0 % Horizons ETFs Management (Canada) Inc.0-36,0908/31/2022
1

Pharmacielo Executives and Management Board

Mr. William Petron
Pharmacielo Lead Independent Director (since 2021)
Compensation 541,681
Mr. Andres Botero
Pharmacielo Chief Operating Officer
Compensation 290,569
Mr. Ian Atacan
Pharmacielo Chief Financial Officer, Director (since 2021)
Compensation 275,000
Mr. William Nicholas67
Pharmacielo Independent Director
Compensation 97,132
Mr. Douglas Bache
Pharmacielo Independent Director
Compensation 60,000
1
2

Most common questions regarding Pharmacielo

What values and corporate philosophy does Pharmacielo represent?

Pharmacielo Ltd represents a strong set of values and corporate philosophy in its operations. The company is committed to providing high-quality pharmaceutical-grade cannabis products to improve people's lives. Pharmacielo focuses on sustainability, innovation, and research to ensure the highest standards of cultivation and production. With a customer-centric approach, Pharmacielo strives to deliver value and satisfaction to its stakeholders. The company embraces transparency, integrity, and accountability, promoting ethical practices throughout its operations. Pharmacielo Ltd's dedication to excellence and its commitment to improving the well-being of individuals make it a leading player in the cannabis industry.

In which countries and regions is Pharmacielo primarily present?

Pharmacielo Ltd is primarily present in Colombia, which serves as its main operating base and headquarters. With a focus on medicinal-grade cannabis, Pharmacielo is one of the leading companies in the country's rapidly growing cannabis industry. Additionally, the company has expanded its presence into other key regions such as Peru and Uruguay, further establishing its footprint in the Latin American market. As Pharmacielo continues to expand its operations, it remains dedicated to producing high-quality cannabis products and driving innovation in the global cannabis industry.

What significant milestones has the company Pharmacielo achieved?

Pharmacielo Ltd has achieved several significant milestones. Firstly, the company obtained its medical cannabis cultivation license in Colombia, allowing it to cultivate and process cannabis plants. Additionally, Pharmacielo secured its Good Manufacturing Practices (GMP) certification, indicating adherence to quality and safety standards in pharmaceutical manufacturing. The company successfully exported its first commercial shipment of medicinal cannabis oil to Canada, marking a crucial step in expanding its international market presence. Furthermore, Pharmacielo received approval to cultivate and process cannabis in Portugal, enabling access to the European Union market. These achievements demonstrate Pharmacielo's commitment to becoming a global leader in the medicinal cannabis industry.

What is the history and background of the company Pharmacielo?

Pharmacielo Ltd is a leading global company in the cannabis industry. Founded in 2017, Pharmacielo has quickly gained prominence due to its strategic presence in Colombia, where it leverages the ideal climate and low-cost production advantages for cannabis cultivation. The company is focused on the cultivation, processing, and production of high-quality medicinal-grade cannabis oils and extracts. With a commitment to sustainability and innovation, Pharmacielo has established itself as a reliable producer and supplier of cannabis products, meeting the growing demand for medical cannabis globally. Emphasizing rigorous quality control and compliance with international standards, Pharmacielo Ltd strives to be a market leader in the rapidly expanding cannabis industry.

Who are the main competitors of Pharmacielo in the market?

Some of the main competitors of Pharmacielo Ltd in the market include Canopy Growth Corporation, Aurora Cannabis Inc., and Aphria Inc.

In which industries is Pharmacielo primarily active?

Pharmacielo Ltd is primarily active in the cannabis industry.

What is the business model of Pharmacielo?

The business model of Pharmacielo Ltd focuses on the cultivation, production, and distribution of medicinal-grade cannabis oil extracts and related products. As a leading global company in the cannabis industry, Pharmacielo Ltd aims to supply high-quality medicinal cannabis extracts to meet the increasing global demand. By leveraging their expertise in agriculture, pharmaceuticals, and innovation, Pharmacielo Ltd strives to deliver safe and effective cannabis-based medical solutions. With their vertically integrated operations, which include cultivation facilities, extraction labs, and distribution networks, the company is optimizing its supply chain to ensure consistent product quality, while also expanding its market reach to serve patients and healthcare providers across the globe.

What is the P/E ratio of Pharmacielo 2024?

The Pharmacielo P/E ratio is 0.65.

What is the P/S ratio of Pharmacielo 2024?

The Pharmacielo P/S ratio is 0.16.

What is the AlleAktien quality score of Pharmacielo?

The AlleAktien quality score for Pharmacielo is 2/10.

What is the revenue of Pharmacielo 2024?

The expected Pharmacielo revenue is 118.49 M CAD.

How high is the profit of Pharmacielo 2024?

The expected Pharmacielo profit is 28.36 M CAD.

What is the business model of Pharmacielo

Pharmacielo Ltd is a Canadian company specialized in the production and sale of medical cannabis. They operate in three different areas: cultivation, processing, and distribution of cannabis products. The company focuses on vertical integration to ensure a high-quality production chain. They have cultivation areas in Colombia, which provide ideal conditions due to the tropical climate. Continuous monitoring and inspections by both the company and government agencies secure the cultivation areas. The processing of the cannabis flowers and harvest takes place in a state-of-the-art facility certified according to international standards. Different technologies are employed to produce a high-quality end product. In the distribution sector, Pharmacielo offers various products based on medical cannabis, including oils, extracts, tinctures, suppositories, and capsules. The company's aim is to produce high-quality standardized products to ensure consistent product quality. Pharmacielo sells its products to end customers as well as wholesalers who further distribute the products. Pharmacielo's business model is based on a wholesale approach. This means that the company produces products at a wholesale level and sells them to other companies that resell the products under their own name or as the Pharmacielo brand. This relieves Pharmacielo from the distribution costs, which are taken over by the other companies. The advantage of the wholesale business model is that it allows the company to distribute its products on a broader scale while bearing only a fraction of the costs that individual sales would entail. To continue their success, Pharmacielo focuses on developing new products and expanding into new markets. The company relies on its expertise and knowledge in the production of medical cannabis. The aim is to expand the range of roll-on organic certified oils, tinctures, and capsules in order to better meet customer needs. Expanding the product offering is also an important step to differentiate from competitors and tap into new customers and markets. All in all, we can say that Pharmacielo is a profitable company that has established itself in the market for medical cannabis. They have a vertically integrated production chain that allows them to continuously produce high-quality products. The wholesale business model enables Pharmacielo to distribute its products widely and save costs. Expanding the product offering and entering new markets are the keys to the company's growth.

What is the Pharmacielo dividend?

Pharmacielo pays a dividend of 0 CAD distributed over payouts per year.

How often does Pharmacielo pay dividends?

The dividend cannot currently be calculated for Pharmacielo or the company does not pay out a dividend.

What is the Pharmacielo ISIN?

The ISIN of Pharmacielo is CA71716K1012.

What is the Pharmacielo WKN?

The WKN of Pharmacielo is A2PCAX.

What is the Pharmacielo ticker?

The ticker of Pharmacielo is PCLO.V.

How much dividend does Pharmacielo pay?

Over the past 12 months, Pharmacielo paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmacielo is expected to pay a dividend of 0 CAD.

What is the dividend yield of Pharmacielo?

The current dividend yield of Pharmacielo is .

When does Pharmacielo pay dividends?

Pharmacielo pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharmacielo?

Pharmacielo paid dividends every year for the past 0 years.

What is the dividend of Pharmacielo?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharmacielo located?

Pharmacielo is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharmacielo kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharmacielo from 9/20/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Pharmacielo pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Pharmacielo in the year 2023?

In the year 2023, Pharmacielo distributed 0 CAD as dividends.

In which currency does Pharmacielo pay out the dividend?

The dividends of Pharmacielo are distributed in CAD.

All fundamentals about Pharmacielo

Our stock analysis for Pharmacielo Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmacielo Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.